Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer

被引：0
|
作者：
Kelly K. Hunt
Vera J. Suman
Hannah F. Wingate
A. Marilyn Leitch
Gary Unzeitig
Judy C. Boughey
Funda Meric-Bernstam
Matthew J. Ellis
John Olson
机构：
[1] UT MD Anderson Cancer Center,Breast Surgical Oncology
[2] Mayo Clinic,Alliance Statistics and Data Management Center
[3] University of Texas Southwestern Medical Center,Lester and Sue Smith Breast Center
[4] Doctor’s Hospital of Laredo,Greenebaum Cancer Center
[5] Mayo Clinic,undefined
[6] Baylor College of Medicine,undefined
[7] University of Maryland,undefined
来源：
Annals of Surgical Oncology | 2023年 / 30卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2111 / 2118
页数：7
相关论文
共 50 条
  • [1] Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer
    Hunt, Kelly K. K.
    Suman, Vera J. J.
    Wingate, Hannah F. F.
    Leitch, A. Marilyn
    Unzeitig, Gary
    Boughey, Judy C. C.
    Meric-Bernstam, Funda
    Ellis, Matthew J. J.
    Olson, John
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (04) : 2111 - 2118
  • [2] ASO Visual Abstract: Local-Regional Recurrence Following Neoadjuvant Endocrine Therapy - Data from ACOSOG Z1031 (Alliance), a Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2-3 Breast Cancer
    Hunt, Kelly K. K.
    Suman, Vera J. J.
    Wingate, Hannah F. F.
    Leitch, A. Marilyn
    Unzeitig, Gary
    Boughey, Judy C. C.
    Meric-Bernstam, Funda
    Ellis, Matthew J. J.
    Olson, John A. A.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (04) : 2119 - 2120
  • [3] ASO Visual Abstract: Local-Regional Recurrence Following Neoadjuvant Endocrine Therapy – Data from ACOSOG Z1031 (Alliance), a Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor–Positive Clinical Stage 2–3 Breast Cancer
    Kelly K. Hunt
    Vera J. Suman
    Hannah F. Wingate
    A. Marilyn Leitch
    Gary Unzeitig
    Judy C. Boughey
    Funda Meric-Bernstam
    Matthew J. Ellis
    John A. Olson
    [J]. Annals of Surgical Oncology, 2023, 30 : 2119 - 2120
  • [4] ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer
    Ellis, M. J.
    Babiera, G.
    Unzeitig, G. W.
    Marcom, P. K.
    Guenther, J. M.
    Deshryver, F. K.
    Allred, D. C.
    Suman, V.
    Hunt, K.
    Olson, J. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [5] Local-regional Recurrence (LRR) Following Neoadjuvant Endocrine Therapy (NET): Data from ACOSOG Z1031 (Alliance)
    Hunt, K.
    Suman, V. J.
    Leitch, M.
    Unzeitig, G.
    Boughey, J. C.
    Meric-Bernstam, F.
    Olson, J. A.
    Ellis, M. J.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S7 - S7
  • [6] Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031
    Ellis, Matthew J.
    Suman, Vera J.
    Hoog, Jeremy
    Lin, Li
    Snider, Jacqueline
    Prat, Aleix
    Parker, Joel S.
    Luo, Jingqin
    DeSchryver, Katherine
    Allred, D. Craig
    Esserman, Laura J.
    Unzeitig, Gary W.
    Margenthaler, Julie
    Babiera, Gildy V.
    Marcom, P. Kelly
    Guenther, Joseph M.
    Watson, Mark A.
    Leitch, Marilyn
    Hunt, Kelly
    Olson, John A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) : 2342 - 2349
  • [7] ACOSOG Z1031: A Randomized Neoadjuvant Comparison between Letrozole (LET), Anastrozole (ANA) and Exemestane (EXE) for Postmenopausal Women with ER Rich Stage 2/3 Breast Cancer: Biomarker Outcomes and the Predictive Value of the Baseline PAM50 Based Intrinsic Subtype
    Ellis, M.
    Suman, V.
    Hoog, J.
    Lin, L.
    Snider, J.
    Parker, J.
    Deshryver, K.
    Watson, M.
    Allred, C.
    Hunt, K.
    Olson, J.
    [J]. CANCER RESEARCH, 2010, 70
  • [8] Tumor Response to Neoadjuvant Chemotherapy Compared to Neoadjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor Positive Stage 2 to 3 Breast Cancer
    Tammaro, Yolanda
    Moses, Gregory
    Eastman, Amy
    Peng, Yan
    Euhus, David
    Leitch, A. Marilyn
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : 110 - 111
  • [9] Assessment of Pathologic Tumor Response to Neoadjuvant Endocrine Therapy in Postmenopausal Women with Estrogen Receptor Positive Stage 2 or 3 Breast Cancer
    Tammaro, Y. R.
    Moses, G.
    Eastman, A.
    Peng, Y.
    Euhus, D.
    Leitch, A.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : S87 - S87
  • [10] A short-term neoadjuvant pilot study comparing exemestane and letrozole in postmenopausal women with estrogen receptor-positive HER2-negative breast cancer
    Miura, Daishu
    Iwatani, Tsuguo
    Kawabata, Hidetaka
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345